Clinical trials: Moderate to Severe Dry Eye
Sjögren's Syndrome
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from…
- Trial name
- NCT02843659
- Testing
- BMS-931699, BMS-986142
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Dry Eye Syndrome
Efficacy, Safety of T2769 in Dry Eye Disease
Efficacy of T2769 in Dry Eye Desease
- Trial name
- NCT03830359
- Testing
- T2769
- Where
- 3 sites in Tunisia
- Volunteers
- 62 people
- Sponsor
- Laboratoires Thea
Dry Eye Syndromes
A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief
A study to evaluate the tolerability and acceptability of an investigational eye drop formulation in patients with Dry Eye Disease.
- Trial name
- NCT02455050
- Testing
- Carboxymethylcellulose Sodium Based Eye Drops, Systane® Gel Drops, Genteal® Lubricant Gel Drops
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Allergan
Dry Eye Syndrome
Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Comparison of the efficacy and safety of T2762 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
- Trial name
- NCT02023268
- Testing
- T2762, Vismed®
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Laboratoires Thea
Dry Eye Syndromes
Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease
This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on results from Stage 1.
- Trial name
- NCT02013791
- Testing
- Vehicle, Cyclosporine New Ophthalmic Formulation
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Allergan
Keratoconjunctivitis Sicca
Trial of CF101 to Treat Patients With Dry Eye Disease
Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.
- Trial name
- NCT01235234
- Testing
- CF101
- Where
- Israel
- Volunteers
- 236 people
- Sponsor
- Can-Fite BioPharma
Dry Eye Syndrome
Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.
The objective is to demonstrate the non-inferiority of T2769 compared to Hylo-Forte® in terms of the change from baseline (D1) in total ocular surface staining score assessed on Oxford 0-15 scale, in the study eye at the D36…
- Trial name
- NCT06375499
- Testing
- T2769, Hylo-Forte®
- Where
- 4 sites in Czechia, Hungary
- Volunteers
- 74 people
- Sponsor
- Laboratoires Thea
Sjögren Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome.
- Trial name
- LOUiSSe (NCT04035668)
- Testing
- Remibrutinib
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndromes
Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
Comparison of the efficacy and safety of T2750 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
- Trial name
- NCT01568593
- Testing
- T2750, Vismed
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease
A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease
The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 in adult subjects with moderate to severe dry eye disease.
- Trial name
- NCT04084483
- Testing
- K-161
- Where
- 4 sites in United States
- Volunteers
- 238 people
- Sponsor
- Kowa Research Institute, Inc.
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Dry Eye
A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye
The purpose of this study is to compare the efficacy and safety of HBM9036 Ophthalmic Solution versus placebo in the treatment of dry eye
- Trial name
- NCT04092907
- Testing
- HBM9036 0.25% Ophthalmic Solution
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Dry Eye
Performance and Safety of T2769 in DED
To demonstrate the non-inferiority of T2769 compared to Vismed® Multi in terms of total ocular surface staining (Oxford score) after 35 days of treatment. To evaluate the performance and safety of T2769 versus Vismed® Multi.
- Trial name
- NCT05965778
- Testing
- T2769, Vismed® Multi
- Where
- France
- Volunteers
- 251 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.
- Trial name
- NCT05403827
- Testing
- K-161
- Where
- 51 sites in United States
- Volunteers
- 644 people
- Sponsor
- Kowa Research Institute, Inc.
Dry Eye Syndromes
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry…
- Trial name
- NCT02617667
- Testing
- Cyclosporine A
- Where
- 4 sites in United States
- Volunteers
- 207 people
- Sponsor
- Novaliq GmbH
Dry Eye Syndrome
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
The objective of this study is to assess the efficacy and safety of rhNGF eye drops at 20 μg/ml concentration administered two or three times daily for 4 weeks in patients with moderate to severe dry eye.
- Trial name
- NCT03982368
- Testing
- rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle
- Where
- 12 sites in United States
- Volunteers
- 261 people
- Sponsor
- Dompé Farmaceutici S.p.A